Literature DB >> 18221634

Weight gain and metabolic issues of medicines used for bipolar disorder.

Andrea Fagiolini1, K N Roy Chengappa.   

Abstract

Patients with bipolar disorder are at high risk of gaining weight and developing metabolic illnesses, and pharmacologic treatment for the disorder may significantly increase this risk. This paper reviews the literature on the metabolic consequences of the medications used in bipolar disorder and describes the possible strategies to prevent, monitor, and treat the common metabolic illnesses that patients with bipolar disorder may develop during treatment.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18221634     DOI： 10.1007/s11920-007-0071-1

Source DB:  PubMed          Journal:  Curr Psychiatry Rep        ISSN： 1523-3812            Impact factor:   8.081


  62 in total

1.  Changes in body weight and body mass index among psychiatric patients receiving lithium, valproate, or topiramate: an open-label, nonrandomized chart review.

Authors:  K N Roy Chengappa; L Chalasani; Jaspreet S Brar; H Parepally; Patricia Houck; Joseph Levine
Journal:  Clin Ther       Date:  2002-10       Impact factor: 3.393

Review 2.  Lithium-induced subclinical hypothyroidism: review of the literature and guidelines for treatment.

Authors:  J Kleiner; L Altshuler; V Hendrick; J M Hershman
Journal:  J Clin Psychiatry       Date:  1999-04       Impact factor: 4.384

3.  Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo.

Authors:  Margaret O Sowell; Nitai Mukhopadhyay; Patrizia Cavazzoni; Sudha Shankar; Helmut O Steinberg; Alan Breier; Charles M Beasley; Jamie Dananberg
Journal:  J Clin Endocrinol Metab       Date:  2002-06       Impact factor: 5.958

4.  An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients.

Authors:  Carol E Koro; Donald O Fedder; Gilbert J L'Italien; Sheila Weiss; Laurence S Magder; Julie Kreyenbuhl; Dennis Revicki; Robert W Buchanan
Journal:  Arch Gen Psychiatry       Date:  2002-11

Review 5.  Lithium: a review of its metabolic adverse effects.

Authors:  Callum Livingstone; Hagan Rampes
Journal:  J Psychopharmacol       Date:  2005-09-20       Impact factor: 4.153

6.  Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians.

Authors:  Andrea Fagiolini; Ellen Frank; John A Scott; Scott Turkin; David J Kupfer
Journal:  Bipolar Disord       Date:  2005-10       Impact factor: 6.744

7.  Hyperprolactinemia and amenorrhea associated with olanzapine normalized after addition of aripiprazole.

Authors:  J Wolf; U Fiedler
Journal:  J Clin Pharm Ther       Date:  2007-04       Impact factor: 2.512

8.  Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study.

Authors:  Daniel E Casey; William H Carson; Anutosh R Saha; Amy Liebeskind; Mirza W Ali; Darlene Jody; Gary G Ingenito
Journal:  Psychopharmacology (Berl)       Date:  2003-02-28       Impact factor: 4.530

Review 9.  The relationship between polycystic ovary syndrome and antiepileptic drugs: a review of the evidence.

Authors:  Natalie Rasgon
Journal:  J Clin Psychopharmacol       Date:  2004-06       Impact factor: 3.153

10.  Relationship between levels of insulin or triglycerides and serum concentrations of the atypical antipsychotics clozapine and olanzapine in patients on treatment with therapeutic doses.

Authors:  K I Melkersson; M-L Dahl
Journal:  Psychopharmacology (Berl)       Date:  2003-07-08       Impact factor: 4.530
View more
  6 in total

1.  Gender differences in antipsychotics prescribed to veterans with serious mental illness.

Authors:  Elana Schwartz; Melanie Charlotte; Eric Slade; Deborah Medoff; Lan Li; Lisa Dixon; Amy Kilbourne; Julie Kreyenbuhl
Journal:  Gen Hosp Psychiatry       Date:  2015-04-01       Impact factor: 3.238

2.  Management of eating disorders for people with higher weight: clinical practice guideline.

Authors:  Angelique F Ralph; Leah Brennan; Sue Byrne; Belinda Caldwell; Jo Farmer; Laura M Hart; Gabriella A Heruc; Sarah Maguire; Milan K Piya; Julia Quin; Sarah K Trobe; Andrew Wallis; A J Williams-Tchen; Phillipa Hay
Journal:  J Eat Disord       Date:  2022-08-18

Review 3.  A review of the preclinical and clinical evidence for protein kinase C as a target for drug development for bipolar disorder.

Authors:  Nancy DiazGranados; Carlos A Zarate
Journal:  Curr Psychiatry Rep       Date:  2008-12       Impact factor: 5.285

4.  Gender differences in mood stabilizer medications prescribed to Veterans with serious mental illness.

Authors:  Melanie Charlotte; Elana Schwartz; Eric Slade; Deborah Medoff; Lan Li; Lisa Dixon; Amy M Kilbourne; Julie Kreyenbuhl
Journal:  J Affect Disord       Date:  2015-09-03       Impact factor: 4.839

5.  Effect of Tamoxifen and Lithium on Treatment of Acute Mania Symptoms in Children and Adolescents.

Authors:  Elham Fallah; Sorror Arman; Mostafa Najafi; Bahar Shayegh
Journal:  Iran J Child Neurol       Date:  2016

Review 6.  Integrated neurobiology of bipolar disorder.

Authors:  Vladimir Maletic; Charles Raison
Journal:  Front Psychiatry       Date:  2014-08-25       Impact factor: 4.157
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.